Annexon
Annexon Inc is a clinical-stage biopharmaceutical enterprise headquartered in South San Francisco, California. The company discovers and develops novel therapeutics targeting classical complement-mediated autoimmune and neurodegenerative diseases. Its proprietary research pipeline focuses on precision antibody therapies addressing disorders of the brain, eyes, and peripheral nervous systems. Principal revenue is earned through research collaboration agreements, clinical milestone payments, and pharmaceutical development partnerships. The enterprise serves medical researchers, neurology specialists, and clinical healthcare networks. Annexon Inc is publicly traded on the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in Annexon.
- Legal name
- Annexon Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
- Exposure themes
- Ageing & Longevity, Healthy Ageing & Function, Vision
Funds holding Annexon
- DNB Bioteknologi — DNB · 0.8 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.0 % (full portfolio disclosed, September 2026)